These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36983419)

  • 21. Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.
    Li LL; Zheng C; La J; Do NV; Monach PA; Strymish JM; Fillmore NR; Branch-Elliman W
    Vaccine; 2022 Feb; 40(8):1082-1089. PubMed ID: 35078665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study.
    Guijarro C; Galán I; Martínez-Ponce D; Pérez-Fernández E; Goyanes MJ; Castilla V; Velasco M
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e1-1699.e4. PubMed ID: 34197936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
    Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
    Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
    JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose.
    Mochizuki RI; Takahashi N; Ikenouchi K; Shoda W; Kuyama T; Takahashi D
    CEN Case Rep; 2022 Nov; 11(4):477-481. PubMed ID: 35435622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.
    Tu TM; Yi SJ; Koh JS; Saffari SE; Hoe RHM; Chen GJ; Chiew HJ; Tham CH; Seet CYH; Yong MH; Yong KP; Hui AC; Fan BE; Tan BY; Quek AML; Seet RCS; Yeo LLL; Tan K; Thirugnanam UN
    JAMA Netw Open; 2022 Mar; 5(3):e222940. PubMed ID: 35297971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
    Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.
    Prabhu M; Yang YJ; Johnston CD; Murphy EA; Ketas TJ; Diaz-Tapia R; Jurkiewicz M; Racine-Brzostek S; Mohammed I; Sukhu AC; Singh S; Forlenza K; Iyer S; Yee J; Eng D; Marks K; Zhao Z; Klasse PJ; Permar S; Moore JP; Riley LE
    Am J Obstet Gynecol MFM; 2023 Feb; 5(2):100796. PubMed ID: 36334723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.
    Yeo JG; Chia WN; Teh KL; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Lim AJM; Poh SL; Tay SH; Nay Yaung K; Ong XM; Hazirah SN; Chua CJH; Leong JY; Wang LF; Albani S; Arkachaisri T
    Rheumatology (Oxford); 2022 Nov; 61(11):4472-4481. PubMed ID: 35199166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
    Zavala-Flores E; Salcedo-Matienzo J; Quiroz-Alva A; Berrocal-Kasay A
    Clin Rheumatol; 2022 May; 41(5):1349-1357. PubMed ID: 34782941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CVAPPS: A Cross-Sectional Study of SARS-CoV-2 Vaccine Acceptance, Perceptions, and Post-Vaccination Side Effects among Rheumatic Disease Patients in Kuwait.
    Baroun F; Albasri A; Abutiban F; Alhajeri H
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992250
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.
    Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
    Pediatr Nephrol; 2023 Apr; 38(4):1099-1106. PubMed ID: 35913562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal change disease following the Moderna COVID-19 vaccine: first case report.
    Thappy S; Thalappil SR; Abbarh S; Al-Mashdali A; Akhtar M; Alkadi MM
    BMC Nephrol; 2021 Nov; 22(1):376. PubMed ID: 34763669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center.
    Jacobson KB; Pinsky BA; Montez Rath ME; Wang H; Miller JA; Skhiri M; Shepard J; Mathew R; Lee G; Bohman B; Parsonnet J; Holubar M
    Clin Infect Dis; 2022 Mar; 74(5):821-828. PubMed ID: 34137815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines.
    Ritter A; Helmchen B; Gaspert A; Bleisch J; Fritschi B; Buchkremer F; Damm S; Schmid N; Schachtner T; Seeger H
    Clin Kidney J; 2022 May; 15(5):961-973. PubMed ID: 35498904
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.